Healthcare spending in the United Kingdom stood at 317 billion British pounds in 2024. When looking at real healthcare expenditure*, spending already exceeded this amount in 2021, where it reached 324 billion British pounds in 2024 prices. Health expenditure in the UK compared to Europe In 2024, the UK spent almost 11 percent of its GDP on healthcare. In comparison to other European countries, this ranked the UK fifth in terms of health expenditure. At the top of the list was Switzerland, which spent 12 percent of its GDP on healthcare that year.  Performance of the NHS in the UK Waiting times have been getting worse in the A&E department over the years. The NHS has been falling behind the target that 95 percent of patients should be seen within four hours of arrival. As a result, the primary reasons for dissatisfaction with the NHS among the public are the length of time required to get a GP or hospital appointment and the lack of staff.

The healthcare expenditure in 2023 amounted to over *** billion euros. In 2024, the public funding sources in the UK provided **** percent of funding, an increase from **** percent in 1997.

In 2024/25, health spending in the United Kingdom was ***** British pounds per capita, ranging from ***** pounds per capita in London, to ***** pounds per capita in South East England.

This statistic displays the annual public healthcare spending in the United Kingdom from 2000 to 2023. The total public healthcare spending increased over the period concerned to approximately ***** British pounds per capita in 2022, the highest in the provided time interval, before slightly falling to ***** British pounds in 2023.

In 2024, the annual spending on public healthcare in the United Kingdom (UK) accounted for *** percent of GDP. This is an increase from *** percent in 2023. Total spending on health in the UK In total, approximately *** billion British pounds were spent on healthcare in the UK in 2024. Although, spending as a share of GDP decreased from 2009 to 2019, the total spending on health has continued to increase. Broken down by function, the UK government spent *** billion pounds on curative/rehabilitative care. Performance of the NHS in the UK Waiting times have been getting worse in the A&E department over the years. The NHS has been falling behind the target that ** percent of patients should be seen within * hours of arrival. As a result, the primary reasons for dissatisfaction with the NHS among the public are the length of time required to get a GP or hospital appointment and the lack of staff.

Saudi Arabia’s Vision 2030 aims to reform health care across the Kingdom, with health technology assessment being adopted as one tool promising to improve the efficiency with which resources are used. An understanding of the opportunity costs of reimbursement decisions is key to fulfilling this promise and can be used to inform a cost-effectiveness threshold. This paper is the first to provide a range of estimates of this using existing evidence extrapolated to the context of Saudi Arabia. We use four approaches to estimate the marginal cost per unit of health produced by the healthcare system; drawing from existing evidence provided by a cross-country analysis, two alternative estimates from the UK context, and based on extrapolating a UK estimate using evidence on the income elasticity of the value of health. Consequences of estimation error are explored. Based on the four approaches, we find a range of SAR 42,046 per QALY gained (48% of GDP per capita) to SAR 215,120 per QALY gained (246% of GDP per capita). Calculated potential central estimates from the average of estimated health gains based on each source gives a range of SAR 50,000–75,000. The results are in line with estimates from the emerging literature from across the world. A cost-effectiveness threshold reflecting health opportunity costs can aid decision-making. Applying a cost-effectiveness threshold based on the range SAR 50,000 to 75,000 per QALY gained would ensure that resource allocation decisions in healthcare can in be informed in a way that accounts for health opportunity costs. A limitation is that it is not based on a within-country study for Saudi Arabia, which represents a promising line of future work. Healthcare in Saudi Arabia is undergoing wide-ranging reform through Saudi Arabia’s Vision 2030. One aim of these reforms is to ensure that money spent on healthcare generates the most improvement in population health possible. To do this requires understanding the trade-offs that exist: funding one pharmaceutical drug means that same money is not available to fund another pharmaceutical drug. This is relevant whether the new drug would be funded from within the existing budget for healthcare or from an expansion of it. If the drugs apply to the same patient population and have the same price, the question is simply, “which one generates more health?” In reality, we need to compare pharmaceutical drugs for different diseases, patient populations, and at a range of potential prices to understand whether the drug in question would generate more health per riyal spent than what is currently funded by the healthcare system. This paper provides the first estimates of the amount of health, measured in terms of quality adjusted life years (QALYs), generated by the Saudi Arabian healthcare system. We find that the healthcare system generates health at a rate of one QALY produced for every 50,000–75,000 riyals spent (58–86% of GDP per capita). Using the range we estimate to inform cost-effectiveness threshold can aid decision-making.

This summary provides information about the money spent on adult social care by the social services departments of Councils with Adult Social Services Responsibilities (CASSRs) in England. It contains information taken from CASSR administrative systems used to record personal social services expenditure and income. The data are used by central government for public accountability, policy monitoring and national accounts, and by local authorities to assess their performance in relation to their peers. This report combines provisional data from 152 CASSRs provided via the Personal Social Services: Expenditure and Unit Costs return (PSS-EX1) and relates to the period 1 April 2013 to 31 March 2014. Final data for 2013-14 are due to be published in December 2014; after submitting the provisional data underlying this report CASSRs have an opportunity to update their data in response to validation queries from the Health and Social Care Information Centre which assess the integrity of the data. Gross current expenditure has been quoted within this summary unless otherwise stated. National level information is provided by client type and service area in this summary. Trends are generally shown over a five year period where broadly comparable and a ten year comparison is made in relation to gross current expenditure. Data on grants and unit costs are broadly comparable over a four year period only. Due to changes in the composition of social care funding and expenditure over time, caution should be exercised when considering long term trends. For further information see Appendix B. In order to account for some of these changes, information about expenditure on adult social care between 2008-09 and 2013-14, from sources including CASSRs and the NHS, is provided in Appendix C. Data at a regional and CASSR level are available via the National Adult Social Care Intelligence Service (NASCIS). NASCIS provides a set of analytical, querying and reporting tools.

Please note: On 16 May 2014, the file "Personal Social Services Expenditure and Unit Costs - England, 2008-2009: Unit Costs" was added to the publication. This retrospective addition presents all the council and England level unit costs of Adult Social Care council services, based on the final release date. This information was already available on NASCIS and this addition is consistent with all later publications of the "Personal Social Services Expenditure and Unit Costs - England" report. Please note: The "Activity Data 2008-09" file for this publication was corrected on 25 November 2010. The numbers presented in the Day Care/ Day Services have changed in 2008-09 and are now the number of clients receiving day care or day services per week. In 2007-08 this was the number of day care sessions. This change to the labelling had not been made on the previous version of this annex although the numbers were correct. Please note: The last two columns in table 2.2 for cash and real terms increases in expenditure headed "Total Adults PSS" was replaced on 05 November 2010. The columns were the wrong way round in previous versions of this table with the figures for cash terms appearing in the column headed real terms and vice versa. Information on the money spent on social care by Councils with Adult Social Services Responsibilities, during 2008-09. It enables analysis of money spent on different types of provision and different client groups within adult services.

The public and private per capita health expenditure differs significantly by country. As of 2024, the United States had by far the highest public per capita spending worldwide. Moreover, the U.S. had the second-highest private expenditure on health globally, just after Switzerland. Health expenditures globally Health expenditures include the consumption of health goods, services and public health programs as well as insurance and government spending. Globally, health expenditures are on the rise. Among all countries, the average per capita health expenditure is projected to see an increase of over 30 percent from the 2019 totals by the year 2050. Despite the growing expenditures, there are still countries with relatively low health expenditures. The countries with the lowest governmental health expenditure include South Sudan, Eritrea and Bangladesh. Health expenditures spotlight: the U.S. In 2023 the U.S. national health expenditure was at an all-time high. However, the projections indicate that total health expenditures will increase even more. The per capita health expenditures for the U.S. looked equally grim, with 2023 being the most expensive year for health care on record.

Snapshot img

Big Data Spending In Healthcare Sector Market Size 2025-2029

The big data spending in healthcare sector market size is valued to increase by USD 7.78 billion, at a CAGR of 10.2% from 2024 to 2029. Need to improve business efficiency will drive the big data spending in healthcare sector market.

Market Insights

APAC dominated the market and accounted for a 31% growth during the 2025-2029.
By Service - Services segment was valued at USD 5.9 billion in 2023
By Type - Descriptive analytics segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: USD 108.28 million 
Market Future Opportunities 2024: USD 7783.80 million
CAGR from 2024 to 2029 : 10.2%

Market Summary

The healthcare sector's adoption of big data analytics is a global trend that continues to gain momentum, driven by the need to improve business efficiency, enhance patient care, and ensure regulatory compliance. Big data in healthcare refers to the large and complex data sets generated from various sources, including Electronic Health Records, medical devices, and patient-generated data. This data holds immense potential for identifying patterns, predicting outcomes, and driving evidence-based decision-making. One real-world scenario illustrating this is supply chain optimization. Hospitals and healthcare providers can leverage big data analytics to optimize their inventory management, reduce wastage, and ensure timely availability of essential medical supplies.
For instance, predictive analytics can help anticipate demand for specific medical equipment or supplies, enabling healthcare providers to maintain optimal stock levels and minimize the risk of stockouts or overstocking. However, the adoption of big data analytics in healthcare is not without challenges. Data privacy and security concerns related to patients' medical data are a significant concern, with potential risks ranging from data breaches to unauthorized access. Ensuring robust Data security measures and adhering to regulatory guidelines, such as the Health Insurance Portability and Accountability Act (HIPAA) in the US, is essential for maintaining trust and protecting sensitive patient information.
In conclusion, the use of big data analytics in healthcare is a transformative trend that offers numerous benefits, from improved operational efficiency to enhanced patient care and regulatory compliance. However, it also presents challenges related to data privacy and security, which must be addressed to fully realize the potential of this technology.

What will be the size of the Big Data Spending In Healthcare Sector Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

The market continues to evolve, with recent research indicating a significant increase in investments. This growth is driven by the need for improved patient care, regulatory compliance, and cost savings. One trend shaping the market is the adoption of advanced analytics techniques to gain insights from large datasets. For instance, predictive analytics is being used to identify potential health risks and improve patient outcomes.
Additionally, data visualization software and data analytics platforms are essential tools for healthcare organizations to make data-driven decisions. Compliance is another critical area where big data is making a significant impact. With the increasing amount of patient data being generated, there is a growing need for data security and privacy. Data encryption methods and data anonymization techniques are being used to protect sensitive patient information. Budgeting is also a significant consideration for healthcare organizations investing in big data. Cost benefit analysis and statistical modeling are essential tools for evaluating the return on investment of big data initiatives.
As healthcare organizations continue to invest in big data, they must balance the benefits against the costs to ensure they are making informed decisions. In conclusion, the market is experiencing significant growth, driven by the need for improved patient care, regulatory compliance, and cost savings. The adoption of advanced analytics techniques, data visualization software, and data analytics platforms is essential for healthcare organizations to gain insights from large datasets and make data-driven decisions. Additionally, data security and privacy are critical considerations, with data encryption methods and data anonymization techniques being used to protect sensitive patient information.
Budgeting is also a significant consideration, with cost benefit analysis and statistical modeling essential tools for evaluating the return on investment of big data initiatives.

Unpacking the Big Data Spending In Healthcare Sector Market Landscape

In the dynamic healthcare sector, the adoption of big data technologies has become a st

This report and associated annexes are superseded by 'Personal Social Services: Expenditure and Unit Costs - England, 2011-12, Final Release' This report provides provisional information on the money spent on Adult Social Care by Councils with Adult Social Services Responsibilities (CASSRs) in England. It contains information taken from council administrative systems used to record personal social services expenditure and income. The data is used by Central Government for public accountability, policy monitoring and national accounts, and by Local Authorities to assess their performance in relation to their peers.

This Public Health Portfolio (Directly Funded Research - Programme and Training Awards) dataset contains NIHR directly funded research awards where the funding is allocated to an award holder or host organisation to carry out a specific piece of research or complete a training award. The NIHR also invests significantly in centres of excellence, collaborations, services and facilities to support research in England. Collectively these form NIHR infrastructure support. NIHR infrastructure supported projects are available in the Public Health Portfolio (Infrastructure Support) dataset which you can find here.NIHR directly funded research awards (Programmes and Training Awards) that were funded between January 2006 and the present extraction date are eligible for inclusion in this dataset. An agreed inclusion/exclusion criteria is used to categorise awards as public health awards (see below). Following inclusion in the dataset, public health awards are second level coded to one of the four Public Health Outcomes Framework domains. These domains are: (1) wider determinants (2) health improvement (3) health protection (4) healthcare and premature mortality.More information on the Public Health Outcomes Framework domains can be found here.This dataset is updated quarterly to include new NIHR awards categorised as public health awards. Please note that for those Public Health Research Programme projects showing an Award Budget of £0.00, the project is undertaken by an on-call team for example, PHIRST, Public Health Review Team, or Knowledge Mobilisation Team, as part of an ongoing programme of work.Inclusion CriteriaThe NIHR Public Health Overview project team worked with colleagues across NIHR public health research to define the inclusion criteria for NIHR public health research. NIHR directly funded research awards are categorised as public health if they are determined to be ‘investigations of interventions in, or studies of, populations that are anticipated to have an effect on health or on health inequity at a population level.’ This definition of public health is intentionally broad to capture the wide range of NIHR public health research across prevention, health improvement, health protection, and healthcare services (both within and outside of NHS settings). This dataset does not reflect the NIHR’s total investment in public health research. The intention is to showcase a subset of the wider NIHR public health portfolio. This dataset includes NIHR directly funded research awards categorised as public health awards. This dataset does not include public health awards or projects funded by any of the three NIHR Research Schools or NIHR Health Protection Research Units.DisclaimersUsers of this dataset should acknowledge the broad definition of public health that has been used to develop the inclusion criteria for this dataset. Please note that this dataset is currently subject to a limited data quality review. We are working to improve our data collection methodologies. Please also note that some awards may also appear in other NIHR curated datasets. Further InformationFurther information on the individual awards shown in the dataset can be found on the NIHR’s Funding & Awards website here. Further information on individual NIHR Research Programme’s decision making processes for funding health and social care research can be found here.Further information on NIHR’s investment in public health research can be found as follows:The NIHR is one of the main funders of public health research in the UK. Public health research falls within the remit of a range of NIHR Directly Funded Research (Programmes and Training Awards), and NIHR Infrastructure Support. NIHR School for Public Health here.NIHR Public Health Policy Research Unit here. NIHR Health Protection Research Units here.NIHR Public Health Research Programme Health Determinants Research Collaborations (HDRC) here.NIHR Public Health Research Programme Public Health Intervention Responsive Studies Teams (PHIRST) here.

The Secondary Uses Service (SUS +) is a collection of healthcare data required by hospitals and used for planning health care, supporting payments, commissioning policy development and research.

The Secondary Uses Services Payment By Results data set is derived from SUS+ and includes key data in support of the national tariff system which is used to determine the reimbursement of NHS funded care in England.

Following the handover of responsibility for the NHS Payment system from DH to NHS England and NHS improvements (formerly Monitor) in April 2013, PbR was effectively replaced by the National Tariff Payment System (NTPS) in April 2014. This new payment system currently retains the vast majority of PbR policy. Due to the embedded terminology, data item and extract naming consistency, SUS continues to refer PbR in SUS and therefore the terms 'Payment by Results', 'PbR', 'National Tariff Payment System' and 'NTPS' should be considered interchangeable when using SUS or any SUS Guidance.

Payment by Results (PbR) provides a transparent, rules-based national tariff system, used to determine the reimbursement of NHS funded care in England. PbR rewards efficiency, supports patient choice and diversity and encourages activity for sustainable waiting time reductions. Payment is linked to activity and adjusted for casemix. This ensures a fair and consistent basis for hospital funding rather than being reliant principally on historic budgets and the negotiating skills of individual managers. PbR is the payment system in England under which commissioners pay providers of NHS-funded healthcare for each patient seen or treated, considering the complexity of the patient’s healthcare needs. The two fundamental features of PbR are nationally determined currencies and tariffs. Currencies are the unit of healthcare for which a payment is made and can take a number of forms covering different time periods from an outpatient attendance or a stay in hospital, to a year SUS+ PbR Reference Manual v4.64 Copyright © 2019 NHS Digital 5 of care for a long-term condition. Tariffs are the set prices paid for each currency.

PbR currently covers most of the acute healthcare in hospitals, with national tariffs for admitted patient care, outpatient attendances and accident and emergency. This activity is submitted using Commissioning Data Sets (CDS). Current policy intends that the scope of PbR and national tariff will expand in future by introducing currencies and tariffs for mental health, community and other services

Timescales for dissemination can be found under 'Our Service Levels' at the following link: https://digital.nhs.uk/services/data-access-request-service-dars/data-access-request-service-dars-process

The Mental Health Minimum Data Set (MHMDS) was renamed Mental Health and Learning Disabilities Data Set (MHLDDS) following an expansion in scope (from September 2014) to include people in contact with learning disability services for the first time. This monthly statistical release makes available the most recent Mental Health Minimum Dataset (MHMDS) data from April 2013 onwards. Further analysis to support currencies and payment in adult and older people's mental health services was added to the publication of April 2014 final data which can be found in the related links below. These changes are described in the Methodological Change paper referenced below. As well as providing timely data, it presents a wide range of information about care given to users of NHS-funded, secondary mental health services for adults and older people ('secondary mental health services') in England. This information will be of particular interest to organisations involved in giving secondary mental health care to adults and older people, as it presents timely information to support discussions between providers and commissioners of services. The MHMDS Monthly Report now includes the ten nationally recommended quality and outcome indicators to support the implementation of currencies and payment in mental health. For patients, researchers, agencies and the wider public it aims to provide up to date information about the numbers of people using services, spending time in psychiatric hospitals and subject to the Mental Health Act (MHA). Some of these measures are currently experimental analysis.

According to Cognitive Market Research, The Immunotherapy Market was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Europe region is the fastest growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future. Asia Pacific accounted for a market share of over XX% of the global revenue with a market size of USD XX million. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Immunotherapy Market held the highest market revenue share in 2024.

Market Dynamics of The Immunotherapy Market

Key Drivers for The Immunotherapy Market

The rising prevalence of Cancer in Drugs for immunotherapy fuel the Market for Immunotherapy Market

The drugs for the immunotherapy market are being driven by the rising prevalence of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. Factors like unhealthy lifestyle choices contribute to the rise in cancer cases, creating a substantial market for immunotherapy treatments aimed at combating this growing health concern. For instance, in October 2022, Macmillan Cancer Support, the largest UK-based healthcare charity organization, estimated that there will be 3.5 million people with cancer by 2025, 4 million by 2030, and 5.3 million by 2040. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving the drugs for immunotherapy market growth. Source:( https://www.etas.com/en/company/press-releases-etas-to-unveil-pantaris-a-cloud-based-integration-platform-for-development-of-connected-vehicle-systems-at-ces-2023.php) Hence, the increasing prevalence of cancer is a significant driving force behind the growth of the immunotherapy market. Factors such as obesity, smoking, alcohol consumption, and poor dietary habits contribute to the rise in cancer cases globally, propelling the demand for immunotherapy drugs.

Growing Healthcare Spending Fuels Demand for Immunotherapy Market

The market for immunotherapy medications is expected to rise at a faster rate due to rising healthcare costs. The total amount of money spent on medical supplies and services in a certain area or nation during a given time frame is referred to as healthcare expenditure. This sum includes payments for doctor visits, hospital stays, operations, diagnostic tests, and treatments. Individuals, insurance companies, government organizations, and healthcare providers all contribute financial resources to the cost of healthcare to pay for the medications used in immunotherapy and other treatments. For instance, in May 2023, The Office for National Statistics, a UK-based government department, The UK had an increase in healthcare spending of 9.4% in nominal terms and 9.7% in real terms. In the UK, total healthcare spending in 2021 was $367.25 billion (£280.7 billion), pharmaceutical spending was $51.84 billion (£39.6 billion), and preventative care spending more than doubled from the previous year to $45.93 billion (£35.1 billion). Therefore, the increasing healthcare expenditure is driving the growth of the drugs for the immunotherapy market. Source:(https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthcaresystem/bulletins/ukhealthaccounts/2021) Thus the escalating healthcare expenditure worldwide is fueling the demand for immunotherapy medications. As healthcare costs continue to rise, individuals, insurance companies, government bodies, and h...

According to Cognitive Market Research, the global Sexually Transmitted Disease Diagnostic Market size will be USD 11624.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 7.80% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 4301.18 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 3371.19 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 2789.95 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.8% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 441.74 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.8% from 2025 to 2033.
Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 464.99 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.1% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 255.75 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.5% from 2025 to 2033.
Point of Care Test category is the fastest growing segment of the Sexually Transmitted Disease Diagnostic industry

Market Dynamics of Sexually Transmitted Disease Diagnostic Market

Key Drivers for Sexually Transmitted Disease Diagnostic Market

Rising Prevalence of Sexually Transmitted Illnesses to Boost Market Growth

The rising prevalence of sexually transmitted illnesses in different geographical areas is one of the main drivers of growth in the STD diagnosis industry. Since chlamydia, gonorrhea, syphilis, and other infections are so common, there is a pressing need for reliable diagnostic procedures. The demand for diagnostic services has increased dramatically as a result of global public health organizations and governments putting initiatives in place to raise public awareness of the value of early identification and treatment. Additionally, the stigma associated with sexually transmitted diseases is progressively fading, which encourages more people to get tested and diagnosed. For instance, the World Health Organization (WHO), an international institution of the United Nations dedicated to enhancing global public health, reports that over 1 million STIs are contracted daily worldwide. Approximately 374 million new cases of one of the four sexually transmitted diseases—chlamydia, gonorrhea, syphilis, and trichomoniasis—occur year. The market is expected to develop even more as a result of the change in society's perception of sexual health.

https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)#:~:text=STIs%20have%20a%20profound%20impact,and%20trichomoniasis%20(156%20million).

Rising Healthcare Costs to Boost Market Growth

The market for STD diagnostics is anticipated to continue growing as a result of rising healthcare costs. The total amount of money spent over a certain time period on healthcare services, associated products, and related activities within a particular healthcare system or economy is referred to as healthcare expenditure. Because it addresses public health priorities, constitutes a strategic investment in preventive healthcare, and promotes general health and well-being at the individual and community levels, healthcare spending is employed in STD diagnoses. For instance, a report released in May 2024 by the UK government's Office for National Statistics states that total healthcare spending increased by 5.6% in nominal terms between 2022 and 2023, which is a significant rise over the 0.9% growth in 2022. As a result, the market for STD tests is expanding due to increased healthcare costs.

https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthcaresystem/bulletins/ukhealthaccounts/2022and2023#:~:text=Total%20healthcare%20expenditure%20increased%20by%205.6%25%20in%20nominal%20terms%20between,a%204.0%25%20decrease%20in%202022.

Restraint Factor for the Sexually Transmitted Disease Diagnostic Market

Privacy Concerns and the Stigma Associated with STIs Will Limit Market Growth

Despite increased government efforts to raise awa...

National health expenditure in the UK amounted to *** billion British pounds in 2024. Of this, **** billion British pounds were private expenditure through out-of-pocket spending and voluntary health insurance schemes. Meanwhile, the majority of healthcare expenditure in the United Kingdom is publicly funded through the NHS.

The Zambian government has outlined an ambitious rights-based approach to health care provision as outlined in its national health policy. Specifically, the government is determined to achieve universal health coverage (UHC) by providing all its citizens with access to free quality health care services through the public health system. To examine trends and patterns in health expenditures and to identify opportunities for achieving value for money and equity, the Zambian government, with technical and financial support from the World Bank and the U.K. Department for International Development (DFID), conducted a public expenditure review (PER) of the health sector. This review covers 2006−2016 and builds on the PER that was produced in 2009. This report shares the results of the PER and provides key policy recommendations on how to address the existing challenges.